FDA accepts Lyxumia-application
FDA has agreed to review a registration application from Danish Zealand Pharma and its partner Sanofi.
by Kresten Morten Munksgaard
US health authorities has agreed to accepted an application for approval of the diabetes drug, Lyxumia, the FDA announced in a letter to Sanofi, the French parma outfit that has acquired marketing rights for the drug developed by Danish company Zealand Pharma.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
